Clinical Research Directory

Inclusion criteria Retrospective cohort * \>18 years old; * Patients previously included in the ADAPT-CTC trial * Signing written informed consentInclusion Criteria: Prospective cohort * \>18 years old * Histologic confirmation (primary or metastatic tumor) of Acinar Adenocarcinoma of Prostate * Hormone-sensitive OMPC defined as ≤3 metachronous metastases (bone and/or lymph node) detected within the past 6 months with Choline/PSMA PET-CT following prostate specific antigen (PSA) rising after primary treatment (surgery and/or radiotherapy) with curative intent as defined by European Association of Urology criteria (EAU). * Controlled primary tumor * Prior salvage treatment to the primary prostate cancer is allowed. * PSA ≤ 50 ng/mL * Testosterone ≥ 0.5 ng/mL * ADT associated to the primary treatment concluded more than 6 months prior to the enrollment. * Patients eligible for a course of SBRT on bone and/or lymph node metastatic sites * Patients must have a life expectancy ≥ 12 months and an ECOG performance status ≤ 2 * Patients must have normal organ and marrow function defined as: * Leukocytes ≥2000/µL * Absolute Neutrophil Count ≥1000/µL * Platelets ≥50000/µL * Patients amenable to understand and sign written informed consent documents Exclusion Criteria: Prospective cohort * Spinal cord compression or impending spinal cord compression. * Suspected pulmonary and/or liver metastases * Patient receiving any other investigational agents * Patient is participating in a concurrent treatment protocol * Prior treatments for hormone-sensitive OMPC * Serum creatinine \> 3 times the upper limit of normal. * Total bilirubin \> 3 times the upper limit of normal. * Liver Transaminases \> 5-times the upper limit of normal. * Unable to lie flat during or tolerate PET/CT or SBRT. * Previous history of cancer other than non-melanoma skin cancer in the last 5 years * Traumatic bone events in the 4 weeks before PET